LONDON – Epsilogen Ltd. has raised £30.8 million (US$41.5 million) in an oversubscribed series B, after its lead immunoglobulin E (IgE) program delivered positive results in a phase I in advanced solid tumors. The money is to fund a phase Ib trial of the product, Mov18 IgE – the first and only IgE antibody to have made it to the clinic – in platinum-resistant ovarian cancer.
After two years of developing its platform, Vesalius Therapeutics Inc. now has $75 million in its pocket from Flagship Pioneering to understand and treat the diseases that account for 90% of the world’s illnesses. To resolve this massive amount of biological and industry complexity, Doug Cole, Vesalius’ chairman and co-founder and Flagship’s managing partner, noted the distinction between illness and disease. “Illness is what bothers you, it’s the experience of being sick and what the doctor might find when you’re examined,” Cole told BioWorld. “Disease is the mechanistic problem with the biology underlying the illness.”
Dariohealth Corp. and Sanofi U.S., a subsidiary of Paris-based Sanofi SA, inked a strategic agreement that provides Dario with $30 million to speed commercial adoption of the company’s integrated digital therapeutics platform. The company simultaneously announced definitive agreements with institutional investors to purchase approximately 5,342,013 shares of its common stock at $7.49 per share, a deal that will generate about $40 million for the company.
Visby Medical Inc. reeled in more than $100 million in a series E round led by Ping An Voyager Partners. The funds will be used to scale production capacity of Visby’s instrument-free, single-use real-time polymerase chain reaction (RT-PCR) platform from tens to hundreds of thousands of tests per month.
Teclison Ltd. has raised $5.9 million to support further development of its lead candidate, TEC-001, an agent designed to induce tumor necrosis and enhance immune checkpoint inhibitors in solid cancers with liver metastasis. Wtt Investment Ltd., the Taiwan-based family office of the late Taiwanese banker Tsai Wan-tsai, led the financing.
Lepu Biopharma Co. Ltd. started trading on the Hong Kong stock exchange on Wednesday, raising HK$904 million ($115.9 million) in an initial public offering. Trading opened at HK$7.13 per share and slid to HK$6.70 by midday before closing at HK$7.13.
RSS
